BioXcel Therapeutics Inc
BTAI1.775USD
+0.405+29.56%
交易中 （美東）報價延遲15分鐘
9.71M總市值
虧損本益比TTM
關於 BioXcel Therapeutics Inc 公司
BioXcel Therapeutics, Inc. 是一家利用人工智能開發神經科學藥物的生物製藥公司。其子公司 OnkosXcel Therapeutics 開發免疫腫瘤學藥物。該公司最先進的神經科學候選藥物 BXCL501 是一種研究性、專有的口服溶解膜製劑 Dex，正在開發中，用於治療與精神和神經系統疾病相關的躁動。該公司正在繼續開發 BXCL501，用於在家中對與雙相情感障礙或精神分裂症相關的躁動進行潛在的急性治療，以及用於在家中和護理機構中對可能因阿爾茨海默病導致的癡呆症相關的躁動（非日常）進行潛在的急性治療。其最先進的免疫腫瘤學候選藥物 BXCL701 是一種研究性口服先天免疫激活劑，用於治療侵襲性前列腺癌、胰腺癌以及其他實體和液體腫瘤。
公司簡介
公司代碼BTAI
公司名稱BioXcel Therapeutics Inc
上市日期Mar 08, 2018
CEODr. Vimal Mehta, Ph.D.
員工數量37
證券類型Ordinary Share
年結日Mar 08
公司地址555 Long Wharf Dr
城市NEW HAVEN
上市交易所NASDAQ Capital Market Consolidated
國家United States of America
郵編06511-6107
電話12036438060
網址https://www.bioxceltherapeutics.com/
公司代碼BTAI
上市日期Mar 08, 2018
CEODr. Vimal Mehta, Ph.D.
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. Vimal Mehta, Ph.D.
Dr. Vimal Mehta, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
19.80K
+373.89%
Mr. David J. Mack
Mr. David J. Mack
Independent Director
Independent Director
18.62K
+10.00%
Dr. Michal Votruba, M.D., Ph.D.
Dr. Michal Votruba, M.D., Ph.D.
Independent Director
Independent Director
11.52K
--
Dr. Peter Mueller, Ph.D.
Dr. Peter Mueller, Ph.D.
Lead Independent Chairman of the Board
Lead Independent Chairman of the Board
7.49K
-42.90%
Mr. Javier Rodriguez
Mr. Javier Rodriguez
Senior Vice President, Chief Legal Officer, Corporate Secretary
Senior Vice President, Chief Legal Officer, Corporate Secretary
6.66K
+301.39%
Mr. Richard I. Steinhart
Mr. Richard I. Steinhart
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
6.44K
+346.98%
Mr. Erik Kopp
Mr. Erik Kopp
Investor Relations
Investor Relations
--
--
DR. Frank D. Yocca ,Ph.D.
DR. Frank D. Yocca ,Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
--
--
Dr. Rajiv Patni, M.D.
Dr. Rajiv Patni, M.D.
Independent Director
Independent Director
--
--
Ms. June Bray
Ms. June Bray
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Vimal Mehta, Ph.D.
Dr. Vimal Mehta, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
19.80K
+373.89%
Mr. David J. Mack
Mr. David J. Mack
Independent Director
Independent Director
18.62K
+10.00%
Dr. Michal Votruba, M.D., Ph.D.
Dr. Michal Votruba, M.D., Ph.D.
Independent Director
Independent Director
11.52K
--
Dr. Peter Mueller, Ph.D.
Dr. Peter Mueller, Ph.D.
Lead Independent Chairman of the Board
Lead Independent Chairman of the Board
7.49K
-42.90%
Mr. Javier Rodriguez
Mr. Javier Rodriguez
Senior Vice President, Chief Legal Officer, Corporate Secretary
Senior Vice President, Chief Legal Officer, Corporate Secretary
6.66K
+301.39%
Mr. Richard I. Steinhart
Mr. Richard I. Steinhart
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
6.44K
+346.98%
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 7月24日 週四
更新時間: 7月24日 週四
持股股東
股東類型
持股股東
持股股東
佔比
Bioxcel Corp
7.93%
Armistice Capital LLC
4.76%
Murchinson Ltd.
2.25%
UBS Financial Services, Inc.
1.68%
Goldman Sachs & Company, Inc.
0.41%
Other
82.97%
持股股東
持股股東
佔比
Bioxcel Corp
7.93%
Armistice Capital LLC
4.76%
Murchinson Ltd.
2.25%
UBS Financial Services, Inc.
1.68%
Goldman Sachs & Company, Inc.
0.41%
Other
82.97%
股東類型
持股股東
佔比
Corporation
7.93%
Hedge Fund
4.76%
Investment Advisor
2.76%
Investment Advisor/Hedge Fund
2.62%
Individual Investor
1.28%
Research Firm
0.89%
Other
79.75%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
225
1.20M
19.77%
-199.41K
2025Q1
248
1.19M
19.87%
-219.94K
2024Q4
260
1.00M
33.25%
-269.93K
2024Q3
269
724.21K
25.25%
-802.39K
2024Q2
282
1.14M
44.29%
-598.60K
2024Q1
282
1.17M
59.63%
-354.60K
2023Q4
282
1.17M
63.22%
-360.50K
2023Q3
290
1.23M
67.44%
-639.74K
2023Q2
289
1.71M
93.56%
-204.68K
2023Q1
297
1.69M
93.06%
-56.17K
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Bioxcel Corp
480.34K
7.93%
-53.83K
-10.08%
Jun 06, 2024
Armistice Capital LLC
288.13K
4.76%
-24.20K
-7.75%
Mar 31, 2025
Murchinson Ltd.
136.08K
2.25%
+136.08K
--
Mar 31, 2025
UBS Financial Services, Inc.
101.78K
1.68%
+21.97K
+27.53%
Mar 31, 2025
Goldman Sachs & Company, Inc.
24.79K
0.41%
+24.79K
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
22.87K
0.38%
-508.00
-2.17%
Mar 31, 2025
Geode Capital Management, L.L.C.
22.06K
0.36%
+2.56K
+13.15%
Mar 31, 2025
Mehta (Vimal)
4.18K
0.07%
+382.00
+10.06%
Jun 15, 2025
Beacon Pointe Advisors LLC
18.84K
0.31%
+18.84K
--
Mar 31, 2025
The Vanguard Group, Inc.
18.82K
0.31%
+18.82K
--
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
ProShares Hedge Replication ETF
0%
Schwab U.S. Small-Cap ETF
0%
iShares Neuroscience and Healthcare ETF
0%
ProShares UltraPro Russell2000
0%
Schwab U.S. Broad Market ETF
0%
iShares Micro-Cap ETF
0%
iShares Morningstar Small-Cap ETF
0%
Fidelity MSCI Health Care Index ETF
0%
Virtus LifeSci Biotech Clinical Trials ETF
0%
WisdomTree Artificial Intelligence and Innov Fund
0%
查看更多
ProShares Hedge Replication ETF
佔比0%
Schwab U.S. Small-Cap ETF
佔比0%
iShares Neuroscience and Healthcare ETF
佔比0%
ProShares UltraPro Russell2000
佔比0%
Schwab U.S. Broad Market ETF
佔比0%
iShares Micro-Cap ETF
佔比0%
iShares Morningstar Small-Cap ETF
佔比0%
Fidelity MSCI Health Care Index ETF
佔比0%
Virtus LifeSci Biotech Clinical Trials ETF
佔比0%
WisdomTree Artificial Intelligence and Innov Fund
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
Feb 06, 2025
Merger
16<1
Feb 06, 2025
Merger
16<1
Feb 06, 2025
Merger
16<1
Feb 06, 2025
Merger
16<1
公告日期
類型
比率
Feb 06, 2025
Merger
16<1
Feb 06, 2025
Merger
16<1
Feb 06, 2025
Merger
16<1
Feb 06, 2025
Merger
16<1
